Ocugen, Inc. OCGN
0.96 USD +0.01 (+1.09%)
At closeNov 11, 2026, 7:27 PM EST
0.96 0.00 -0.16%
After hours · Nov 11, 7:27 PM ET
0.9115 Day range 1.01
0.691 52-week range 2.73
- YTD
- -28.86%
- 1 year
- -27.79%
News
globenewswire.com Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN MALVERN, Pa. and SYDNEY, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, and…
zacks.com Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises OCGN's Q3 revenues beat estimates. Shares surge 17.4%.
seekingalpha.com Ocugen, Inc. (OCGN) Q3 2026 Earnings Call Transcript Ocugen, Inc. ( OCGN ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Chris Clark - VP of Corporate Communications Shankar Musunuri - Co-Founder, CEO & Chairman Rita…
marketbeat.com Ocugen Q3 Earnings Call Highlights Ocugen NASDAQ: OCGN said its third-quarter progress centered on advancing three retinal gene therapy programs in late-stage development, expanding regional partnerships and establishing a European…
benzinga.com UPDATE: Ocugen Q3 Adj. EPS $(0.06), Inline, Sales $1.951M Beat $1.098M Estimate Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.07) per share from the same period…
zacks.com Ocugen (OCGN) Reports Q3 Loss, Tops Revenue Estimates Ocugen (OCGN) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.07 per share a year ago.
benzinga.com Ocugen Q3 2026 Earnings Call Transcript Ocugen (NASDAQ:OCGN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time…
benzinga.com Ocugen Q3 EPS $(0.01) Beats $(0.06) Estimate, Sales $1.951M Beat $1.098M Estimate Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.06) by 83.33 percent. This is a 85.71 percent increase over losses of $(0.07) per…
globenewswire.com Ocugen Provides Business Update with Third Quarter 2026 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET Received Provisional Approval and Priority Designation for OCU400 in The Bahamas Executed agreement with local partner Global Alliance for…
globenewswire.com Ocugen to Participate in Upcoming November Investor and Industry Conferences MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today…
globenewswire.com Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4 MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a…- benzinga.com Ocugen Executes Licensing Agreement With Roots Pharma And Its Strategic Partner Al-Dhow International For Exclusive Rights To OCU400 For Treatment Of Retinitis Pigmentosa In Middle East And North Africa Region Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapiesExpands access…
globenewswire.com Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa MALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced…
prnewswire.com Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be…
newsfilecorp.com Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the…
globenewswire.com Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate MALVERN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on developing and commercializing novel gene therapies to…
benzinga.com Transcript: Ocugen Q2 2026 Earnings Conference Call Ocugen (NASDAQ:OCGN) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts…
globenewswire.com Ocugen to Participate in Upcoming Scientific Conferences MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today…
globenewswire.com Ocugen to Participate in Upcoming October Investor and Industry Conferences MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today…
benzinga.com Ocugen Receives Bahamas Regulator Provisional Approval For OCU400 Has Been Granted Approval And Priority Designation; The Company Will Supply OCU400 Through An EAP, With Goal Of Treating First RP Patient Within 90 Days Ocugen will provide its investigational modifier gene therapy OCU400 through an expanded access program (EAP), with the goal of enabling the first patient to be treated for retinitis pigmentosa (RP)…
globenewswire.com Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa MALVERN, Pa., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced…
marketbeat.com Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances Ocugen NASDAQ: OCGN is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive…
seekingalpha.com Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical Ocugen is advancing three gene therapy programs—OCU400, OCU410ST, and OCU410—targeting major unmet needs in ophthalmology. I assign OCGN a Buy rating, citing strong clinical data, upcoming pivotal…
benzinga.com What's Happening With Ocugen Stock Thursday? Shares of Ocugen are remaining flat Thursday morning as investors continue to weigh disappointing interim clinical trial data.
benzinga.com HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $9.5 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the price target from $10 to $9.5.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON)…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…
zacks.com OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
benzinga.com Ocugen Announces First Patient Dosed In Global Phase 3 Registrational Trial Of OCU410, Modifier Gene Therapy Candidate For GA Secondary To Dry Age-Related Macular Degeneration The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine…
globenewswire.com Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced…
globenewswire.com Ocugen to Participate in Upcoming September Investor and Industry Conferences MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that…
benzinga.com Ocugen Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $1.488M Beat $888.833K Estimate Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 40 percent decrease over losses of $(0.05) per…- benzinga.com FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration RMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet need The designation could…
benzinga.com Ocugen To Enter License Agreement With Roots Pharmaceutical For Rights To OCU400, Its Novel Modifier Gene Therapy For Retinitis Pigmentosa, In The Middle East And North Africa Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400
benzinga.com Canaccord Genuity Maintains Buy on Ocugen, Lowers Price Target to $11 Canaccord Genuity analyst Whitney Ijem maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the price target from $12 to $11.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Full Transcript: Ocugen Q1 2026 Earnings Call
- benzinga.com Ocugen Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $1.533M Beat $540.000K Estimate Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is a 20 percent decrease over losses of $(0.05) per…
benzinga.com GeneDx Holdings, Duolingo, Kosmos Energy And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Dow futures up 100 pts. Shares of GeneDx Holdings (WGS) down 39.2% after cutting FY26 sales guidance. Other stocks falling in pre-market trading.
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Ocugen Plans To Commence $115M Senior Notes Offering Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced its intention to offer, subject to market…
- benzinga.com HC Wainwright & Co. Maintains Buy on Ocugen, Raises Price Target to $10 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy and raises the price target from $7 to $10.
benzinga.com Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls Ocugen stock falls after Phase 2 OCU410 data for dry AMD trails interim results, despite lesion reduction.- benzinga.com Ocugen's 12-month Data From Phase 2 ArMaDa trial of OCU410 (AAV5-RORA) For Geographic Atrophy Secondary To Dry Age-related Macular Degeneration Demonstrates Statistically Significant Reduction In Lesion Growth Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22%…
- benzinga.com Canaccord Genuity Initiates Coverage On Ocugen with Buy Rating, Announces Price Target of $12 Canaccord Genuity analyst Whitney Ijem initiates coverage on Ocugen (NASDAQ:OCGN) with a Buy rating and announces Price Target of $12.
benzinga.com Why Is Ocugen Stock Soaring Today? Ocugen shares are surging Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated coverage with an Outperform rating and a $10 price target.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Serve Robotics Posts Upbeat Q4 Results, Joins Auna, Acacia Research And Other Big Stocks Moving Higher On Wednesday Dow falls 200+ points as Serve Robotics Inc (NASDAQ: SERV) shares rise 16.2% on better-than-expected earnings and raised sales guidance.
benzinga.com This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst ratings page. Analysts' thoughts on LGND stock.